• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

I'm Long Moderna and Here's Why

The focus when it comes to MRNA is the timing of mRNA-1273, the firm's two dose hopeful protection against Covid.
By STEPHEN GUILFOYLE
Oct 29, 2020 | 10:07 AM EDT
Stocks quotes in this article: MRNA, PFE, BNTX

Sometimes a corporation reports financial results and those results are not the story. Sometimes a preclinical biotech is busy developing 21 messenger RNA vaccine candidates meant to prevent a number of maladies, but the public only cares about one. Maybe not sometimes. Maybe just this time. Maybe just one company. Moderna (MRNA) . There are two vaccines that appear to be closest to releasing data from Phase 3 studies, as the world reaches for protection from Covid. They both used experimental messenger RNA technology to get to this point so quickly. The other, Pfizer (PFE) , in conjunction with BioNTech (BNTX) have already let the public know that they have not seen enough "events" to release interim data as soon as hoped for. Now, attention turns to Moderna.

Moderna reported Q3 EPS of -$0.59, which badly missed consensus. However, the firm posted revenue of $157.91 million, almost doubling expectations and good for year over year growth of 826%. Interestingly, revenue from grants came to $145.7 million, while grants from collaboration efforts amounted to $12.2 million. Add them up? $157.91 million. The firm showed research and development expenses that reached $344.5 million, nearly tripling from a year ago, while administrative costs increased to $48.5 million. Hence, the firm put an operating loss of $235.1 million to the tape. Seemingly not so hot.

The Focus

The focus of the public when it comes to this name is the timing of mRNA-1273, the firm's two dose hopeful protection against Covid. The firm has already taken in $1.1 billion in deposits from governments around the world, waiting on news regarding safety and efficacy. Orders have come in from North America, the Middle East, and most recently Japan. The firm reminds us this morning that Phase 3 testing has been fully enrolled at 30K healthy participants. Of these participants, 37% come from diverse communities, 42% are considered to be "high-risk", and 25,650 have already received their second dose.

On Thursday morning, CEO Stephane Bancel indicated that Moderna expects the data and safety monitoring board to conduct an interim analysis sometime in November. Upon eventually reaching some level of emergency use authorization (which would come from the FDA in the U.S.), Bancel said, "We are actively preparing for the launch of mRNA-1273." Bancel added, "Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to advance mRNA-1273."

Taken from the material provided by the firm this morning, Moderna expects positive net cash provided by operating activities and used for purchase of property and equipment to be between $0.1 billion and $0.3 billion, driven by the already mentioned deposits placed down on mRNA-1273. The firm has a number of other vaccine candidates in the pipeline. We could go into those. Some are close, but none are closer than mRNA-1273, nor will the rest drive either revenue like this, nor attention.

My Thoughts

There's a lot going on here. Last spring, as Covid became reality for so many of us, these shares rallied hard as the name "Moderna" became a household word. At first the shares found support where Fibonacci fas would look for it. As time moved along, baseline support was built and tested on multiple occasions close to the $54 level.

Now, it appears that this support level has evolved into the bottom of a cup that has now developed a handle. First order of business is to recapture the 50 day SMA at $68.29. We see a "take and hold" there and these shares can make another run at the new pivot of $81. MRNA takes that spot and then we are writing about target prices up above $105. A lot has to happen for that to happen, and it will all be reliant upon positive headline risk.

I am long this name, and have traded it, and run with a current net basis of $29.95 adjusting for options sold against the position earlier this year. This is house money, so I don't have to panic, but if I did, it would be down around the 200 day SMA of 53.27, just below established support.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long MRNA, PFE equity.

TAGS: Drug Approvals | Earnings | Investing | Stocks | Technical Analysis | Trading | Biotechnology | Coronavirus

More from Investing

End to China's Recovery Shows Policymakers 'Care About Growth, Just Not Much'

Alex Frew McMillan
Aug 15, 2022 6:12 AM EDT

Poor July numbers erase hopes of a strong second half to the year, where lockdowns and the 'zero-Covid' policy have undermined confidence and activity.

Almost Every Single Chart Has Resistance Overhead

Helene Meisler
Aug 15, 2022 6:00 AM EDT

Unless we get breadth red for some meaningful number of days, we won't get back to even a moderate oversold condition. We simply remain overbought.

Bearish Bets: 3 Stocks You Should Think About Shorting This Week

Bob Lang
Aug 14, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

This Small Advertising-Tech Stock Could Offer a Big Opportunity

Bret Jensen
Aug 14, 2022 7:00 AM EDT

Let's check a covered-call play in PubMatic.

To Improve Your Trading and Investing, Spend More Time on Exit Points

James "Rev Shark" DePorre
Aug 13, 2022 10:00 AM EDT

For many investors, the best way to sell is to have a highly mechanical system that removes subjectivity.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login